Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Part of paid clinical trials in Sacramento, California.
- Sponsor
- University of California, Davis
- Study ID
- NCT07145112
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Laser interstitial thermal therapy — PROCEDUREMRI guided laser
- Lomustine — DRUGGiven orally (PO)
Study Details
This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- Oct 2025
- Primary completion
- Jul 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Laser interstitial thermal therapy (LITT) + Lomustine (CCNU)Laser interstitial thermal therapy (LITT) + Lomustine (CCNU)
Primary Outcome Measure
Safety of the combination of Laser Interstitial Thermal Therapy (LITT) and lomustine in patients with recurrent glioblastoma. [ Time Frame: Up to 6 weeks after first dose of lomustine ]
Central Contacts
- Orwa Aboud, MD, PhD916-734-3772
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95827 | Orwa Aboud, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Sacramento, CA
By condition
By specialty
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPHASE2/PHASE3 · Recruiting · Global Coalition for Adaptive Research · Birmingham, Alabama
- Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young AdultsPHASE1 · Recruiting · Sabine Mueller, MD, PhD · Birmingham, Alabama
- A Trial of RSC-1255 for Treatment of Patients With Advanced MalignanciesPHASE1 · Recruiting · RasCal Therapeutics, Inc. · Los Angeles, California